Transport proteins are the gatekeepers of every living cell, controlling what gets in and what stays out. Without them, cells would be sealed off from nutrients, unable to send electrical signals, and incapable of clearing waste. These proteins, embedded in the fatty lipid bilayer of the cell membrane, come in dozens of families and hundreds of individual types, each tuned to move specific molecules or ions. Some simply open a passageway; others burn chemical fuel to shove cargo against steep concentration gradients. Together they underpin everything from how your muscles contract to how antidepressants work, and mutations in a single one can cause serious disease.
Channels Versus Carriers
The broadest way to split transport proteins is by how they move things. Channels form a pore that ions or small molecules flow through, often millions of ions per second. They do not physically grab each molecule; they just provide a tunnel with the right size and charge to let certain passengers through. Carriers (also called transporters) work differently. They bind a molecule on one side of the membrane, change shape, and release it on the other side. This binding-and-flipping is slower than channel flow, but it lets the cell be far more selective about what crosses and can even push molecules uphill against their natural gradient.
The shape change that carriers undergo is called the alternating-access mechanism: the binding pocket faces outward, accepts cargo, then rocks or twists so it faces inward, releasing the cargo into the cell’s interior. This concept was proposed decades ago and has since been confirmed by structural snapshots of many different transporter families. High-resolution imaging shows that internal bundles of helices rotate or shift, alternately opening and closing a cleft to either side of the membrane.1PubMed Central. The alternating access mechanism of transport as observed in the sodium-hydantoin transporter Mhp1 In a bile acid transporter, for example, a large rigid-body rotation of the substrate-binding domain flips accessibility from outside to inside.2Nature. Structural basis of the alternating-access mechanism in a bile acid transporter Cryo-electron microscopy of a zinc transporter resolved the differences between the inward-facing and outward-facing conformations down to individual atoms, showing a rocking and twisting of a four-helix bundle that controls access to the transport site.3PubMed Central. Structural basis for the alternating access mechanism of the cation diffusion facilitator YiiP
Moving With the Gradient
Some transport proteins simply help molecules that already “want” to cross do so more quickly. Glucose, for instance, cannot easily slip through the oily lipid bilayer on its own, even though cells constantly consume it and keep internal levels low. The GLUT family of glucose transporters solves this problem. These proteins sit in the membrane and shuttle glucose down its concentration gradient without spending any energy. Nearly all human cells rely on one or more GLUT family members for glucose uptake.4PubMed. Glucose transporters: structure, function and consequences of deficiency
Structurally, GLUT proteins have 12 segments that span the membrane, arranged from a repeated building block. Four of these blocks move relative to each other, alternately opening and closing a cleft to the outside or inside of the cell, letting glucose pass through one molecule at a time.5PubMed Central. Structure, function and regulation of mammalian glucose transporters of the SLC2 family This is a textbook example of facilitated diffusion: the protein accelerates transport but does not push glucose against its gradient. GLUT1 is found in most tissues and ensures a baseline supply of glucose, while GLUT4 is especially important in muscle and fat cells, where its availability at the cell surface is tightly controlled by insulin (more on that below).
Pumping Against the Gradient
Cells often need to accumulate molecules at concentrations far higher, or lower, than the surrounding environment. That requires energy. In primary active transport, the protein itself breaks down ATP, the cell’s universal energy currency, to power the move. The most famous example is the sodium-potassium pump, found in virtually every animal cell. It pushes three sodium ions out and pulls two potassium ions in with each cycle of ATP hydrolysis. Because three positive charges leave and only two come back, the pump generates a small but steady outward current, making the inside of the cell slightly negative relative to the outside.6Physiological Reviews. Electrophysiology of the sodium-potassium-ATPase in cardiac cells That electrical imbalance is essential for nerve impulses, muscle contractions, and the regulation of cell volume.
Secondary active transport takes a cleverer approach: instead of burning ATP directly, it piggybacks on a gradient that a primary pump already built. The sodium-glucose cotransporter (SGLT) is a well-studied case. Sodium ions rush back into the cell down the steep gradient created by the sodium-potassium pump, and the SGLT protein harnesses that inflow to drag glucose in alongside it, even when glucose levels inside the cell are already high. This idea was first proposed by Robert Crane in 1960 and has since been confirmed at the structural level.7PubMed. Biology of human sodium glucose transporters Structural studies of human SGLT2 show that sodium binding locks the transporter in an outward-open shape, and sodium release triggers the flip to an inward-open shape, providing direct evidence for the sodium-coupled alternating-access mechanism.8Nature Structural & Molecular Biology. Transport and inhibition mechanism of the human SGLT2–MAP17 glucose transporter
How Ion Channels Pick Their Passengers
Ion channels face a paradox: they need to let the right ions through at enormous speed while blocking the wrong ones. Potassium channels, for instance, must let potassium flow freely while excluding sodium, even though sodium ions are actually smaller. The solution lies in the channel’s selectivity filter, a narrow stretch lined with oxygen atoms arranged in a precise geometric pattern. That pattern mirrors the cage of water molecules that normally surrounds a potassium ion in solution, forming a structure called a square antiprism with eight oxygen atoms at each binding site. When potassium enters the filter, it sheds its water coat and slips into an environment that feels energetically identical, so the swap costs nothing. Sodium, with its different size and hydration shell, cannot make the same penalty-free trade.9PubMed. Potassium channel selectivity is determined by square antiprismatic ion chelation
Speed comes from a process called direct knock-on: multiple fully desolvated potassium ions sit in the filter at once, and strong ion-ion repulsion between them shoves each one through in rapid succession. Simulations and free-energy calculations show that this single principle, naked ions pushing each other through, accounts for both the rapid flow and the strict selectivity of potassium channels.10Nature Chemistry. Direct knock-on of desolvated ions governs strict ion selectivity in K+ channels
Many channels do not stay open all the time. Voltage-gated channels, for example, snap open or shut in response to changes in the electrical charge across the membrane. In voltage-gated sodium channels, a sensor segment called S4 moves about 11.5 ångströms inward when the membrane voltage drops, causing a set of linker “elbows” to tighten around the central pore and prevent it from opening. When the voltage shifts back, S4 slides outward and the pore opens.11PubMed Central. Resting State Structure and Gating Mechanism of a Voltage-gated Sodium Channel Other channels respond to chemical signals rather than voltage. Certain inward-rectifying potassium channels, for instance, are gated by a membrane lipid called PIP2, which binds directly to the channel and triggers a shape change that opens the pore.12PubMed Central. Lipid agonism: The PIP2 paradigm of ligand-gated ion channels PIP2 can also regulate transporters through several mechanisms, including direct binding and altering how the protein is inserted into or removed from the membrane.13PubMed. Complex roles of PIP2 in the regulation of ion channels and transporters
How Cells Move Water Without Letting Protons Sneak Through
Water molecules are small and somewhat polar, yet the cell needs to move large volumes of water rapidly, especially in kidneys, eyes, and the brain. Aquaporins are the dedicated water channels for this job. They form narrow, single-file passages that let water molecules zip through while strictly excluding protons. That proton exclusion is critical: if protons could ride through aquaporins, the electrical and chemical gradients cells depend on would collapse.
The trick is architectural. Two conserved asparagine residues at the center of the channel force the central water molecule to donate hydrogen bonds to its neighbors in a specific orientation. Combined with the electrostatic field generated by two half-membrane-spanning loops, this imposes opposite orientations on water molecules in the upper and lower halves of the channel, making it impossible for a continuous chain of hydrogen bonds, a “proton wire,” to form.14PubMed. Control of the selectivity of the aquaporin water channel family by global orientational tuning Simulations of a related channel, the glycerol facilitator GlpF, confirm that the strongest barrier against proton passage sits right at these conserved motifs, where protein-water electrostatic interactions are strongest.15Biophysical Journal. Water Permeation and Electrostatic Interactions in the Glycerol Uptake Facilitator GlpF The result is a channel that can shuttle billions of water molecules per second while refusing entry to a particle barely a third the size of a water molecule.
ABC Transporters and Drug Resistance
ATP-binding cassette (ABC) transporters are a huge protein superfamily found in organisms from bacteria to humans. They use ATP hydrolysis to pump a wide range of substrates, from lipids and vitamins to toxins and drugs. In medicine, the most consequential member is P-glycoprotein (P-gp), also known as MDR1. P-gp sits in the membranes of intestinal, liver, kidney, and brain cells and pumps foreign compounds out. That is useful for defense against toxins, but it becomes a problem in cancer: tumor cells that overexpress P-gp pump chemotherapy drugs out before they can do their job, drastically reducing drug concentrations inside the cell.16PubMed Central. Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein
The mechanism is not just about drug efflux, though. Experiments with mutant P-gp that cannot hydrolyze ATP show that these mutant proteins still confer partial resistance to cancer-killing drugs. Cells expressing the ATPase-dead mutant could not pump drugs out, yet they showed reduced markers of apoptosis (cell death) when treated with a chemotherapy agent. This suggests P-gp has a dual role: it expels drugs in an ATP-dependent manner and separately suppresses cell death signaling in an ATP-independent manner.17Cell Death & Differentiation. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux Atomic-level modeling of the efflux process indicates that ATP bound at one of P-gp’s two nucleotide-binding sites is preferentially hydrolyzed to power a conformational change in a specific transmembrane helix, consistent with an alternating-site mechanism.18PubMed. Modeling substrate efflux in human P-glycoprotein at the atomic level
When Transport Proteins Go Wrong
Mutations that cripple a single transport protein can produce severe disease. Cystic fibrosis is the clearest example. It is caused by mutations in CFTR, a chloride channel that belongs to the ABC transporter family. The most common mutation, called F508del, affects roughly 80% of people with the disease.19PubMed Central. Functional rescue of F508del-CFTR through revertant mutations introduced by CRISPR base editing F508del damages the protein in two ways: it prevents CFTR from folding properly, so almost none of it reaches the cell surface, and it disrupts the channel’s gating, so even the small amount that does arrive works poorly.20Acta Pharmacologica Sinica. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis The result is thick, sticky mucus in the lungs, pancreas, and other organs because epithelial cells cannot move chloride and water properly.
Corrector drugs like VX-809 (lumacaftor) were developed to address the folding defect, helping more F508del-CFTR protein reach the cell surface.21PubMed Central. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 Newer combination therapies pair correctors with potentiators (which improve the channel’s gating once it arrives at the surface) and have transformed outcomes for many patients. Researchers are also exploring gene-editing strategies, using CRISPR base editing to introduce compensatory mutations that restore CFTR folding and function at the DNA level.19PubMed Central. Functional rescue of F508del-CFTR through revertant mutations introduced by CRISPR base editing
Drugs That Target Transport Proteins
Transport proteins are prime drug targets because blocking or tweaking them can profoundly alter cell behavior. Selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed antidepressants, work by blocking the serotonin transporter (SERT) on presynaptic neurons. Normally, SERT recycles serotonin from the synaptic gap back into the neuron, terminating the signal. SSRIs sit in SERT’s central substrate binding site and lock the transporter in an outward-open shape, preventing serotonin from being recaptured.22PubMed Central. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures That keeps serotonin lingering in the synapse longer, strengthening the signal. Different antidepressant classes, including tricyclics and serotonin-norepinephrine reuptake inhibitors, bind SERT at distinct locations, which explains their varying side-effect profiles.23PubMed. Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies
Heart-failure drugs called cardiac glycosides, such as digoxin and ouabain, target the sodium-potassium pump. By inserting deep into the pump’s transmembrane domain and blocking the pathway that extracellular potassium normally uses, these drugs slow sodium export. Rising sodium inside the cell indirectly boosts calcium levels, strengthening the heart’s contraction. Crystal structures show that ouabain lodges with its lactone ring very close to the bound potassium, explaining why high potassium levels in the blood reduce the drug’s effectiveness (the two compete for overlapping territory).24PubMed Central. Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain Comparing structures of the pump bound to digoxin, bufalin, and ouabain reveals a shared general mechanism of inhibition, but subtle differences in how each drug fits the binding cavity and how it interacts with the cation-binding sites.25PubMed Central. Structures and characterization of digoxin- and bufalin-bound Na+,K+-ATPase compared with the ouabain-bound complex
SGLT2 inhibitors are a newer class of diabetes drugs that block the sodium-glucose cotransporter in the kidney, preventing glucose from being reabsorbed back into the blood and instead letting it leave in the urine. Structural work on human SGLT2 has revealed the precise binding pocket these inhibitors occupy, opening the door to more selective drug design.8Nature Structural & Molecular Biology. Transport and inhibition mechanism of the human SGLT2–MAP17 glucose transporter
Insulin, GLUT4, and On-Demand Delivery
Not all regulation happens at the protein’s own structure. Sometimes the cell controls transport by deciding whether a transporter is even present at the membrane. GLUT4, the glucose transporter in muscle and fat cells, spends most of its time tucked away inside the cell in small vesicles. When insulin arrives, it sets off a signaling cascade that drives those vesicles to fuse with the outer membrane, flooding the cell surface with GLUT4 and rapidly increasing glucose uptake.26PubMed Central. Insulin signalling and GLUT4 trafficking in insulin resistance This system requires a specific membrane lipid signal; blocking the enzyme that generates that lipid reduces GLUT4 arrival at the surface, while removing a phosphatase that degrades the lipid enhances it.27PubMed Central. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP)
The docking process itself involves specialized protein complexes that assemble at lipid-rich patches in the membrane called lipid rafts. GLUT4 vesicles briefly associate with these microdomains upon insulin stimulation, and the tethering complex assembles at the raft to pull them in.28PubMed Central. Compartmentalization of the exocyst complex in lipid rafts controls Glut4 vesicle tethering In insulin resistance and type 2 diabetes, this trafficking process is impaired: the signaling cascade weakens, fewer GLUT4 molecules reach the surface, and glucose builds up in the blood. Understanding the exact steps in the pathway has become a major focus for developing therapies that could restore normal glucose uptake.
The Proton-Motive Force
In mitochondria and bacteria, entire energy economies run on transport proteins. Electron-transport chain complexes pump protons across a membrane, creating a steep gradient of both charge and concentration, called the proton-motive force. This gradient is then used by ATP synthase, another membrane protein, to produce ATP as protons flow back through it. The proton-motive force is foundational to how eukaryotic cells produce energy.29PubMed. Roles for Electrochemical Proton Gradients in Mitochondrial Energy Production and Neurosensory Processes in Health and Disease Modeling of bacterial systems shows that a redox-loop shuttle mechanism can push protons against a voltage gradient exceeding 200 millivolts, with a thermodynamic efficiency around 37%.30PubMed. Diffusion-controlled generation of a proton-motive force across a biomembrane Plants use a proton-based version of secondary active transport for much of their nutrient uptake, relying on proton pumps the way animal cells rely on the sodium-potassium pump to set up driving gradients for other transporters.31PubMed Central. The Tiny Companion Matters: The Important Role of Protons in Active Transports in Plants
Seeing Transport Proteins Up Close
Much of what we now know about how transport proteins work comes from advances in structural biology, particularly cryo-electron microscopy (cryo-EM). In this technique, proteins are flash-frozen and imaged by an electron beam, producing three-dimensional structures without the need for protein crystals, which membrane proteins are notoriously difficult to grow. Cryo-EM has become a dominant tool for resolving membrane transporter structures at near-atomic resolution, even from impure or mixed samples.32PubMed. Cryo-electron microscopy (Cryo-EM) structural determination of the MmpL family of transporters Over the past two decades, these advances have dramatically expanded the catalog of known transporter structures and their conformational states.33PubMed Central. How Cryo-EM Has Expanded Our Understanding of Membrane Transporters
A recent example illustrates the power of the approach: researchers used cryo-EM on human red blood cell membranes reconstituted in lipid nanodiscs to capture five distinct structural snapshots of the band 3 transporter, the protein responsible for swapping chloride and bicarbonate across red blood cells. The structures, captured with and without bound ions, suggest a transport mechanism in which both ions move in a coupled fashion.34PubMed Central. Cryo-EM structures of the human band 3 transporter indicate a transport mechanism involving the coupled movement of chloride and bicarbonate ions This kind of multi-state structural dataset would have been almost impossible to obtain even fifteen years ago.
Light-Controlled Channels and Synthetic Biology
Transport proteins are not just objects of study; they are becoming tools. In optogenetics, researchers use light-sensitive ion channels to control the activity of specific neurons in living animals. The original tools were naturally occurring light-gated channels, but engineers have now built synthetic versions by fusing a bacterial light-activated enzyme to ion channels with tailored selectivity. One set of fusion constructs produced light-gated channels permeable to calcium, and another set created light-gated potassium-selective channels. Both showed strong light-triggered conductance in neurons and could control the movement of fruit-fly larvae when expressed in motor neurons.35PubMed Central. Synthetic Light-Activated Ion Channels for Optogenetic Activation and Inhibition Ongoing engineering efforts continue to expand the palette of light-sensitive channel actuators with diverse ion selectivities and spectral sensitivities, aiming for tools that can be tuned to specific wavelengths and specific ions for precise control of cell behavior.36PubMed Central. Optogenetic engineering for ion channel modulation The long-term vision extends well beyond neuroscience: synthetic transport proteins could eventually be used in drug delivery, biosensing, and the design of artificial cells with programmable membrane functions.